- Home
- TYRA vs KELYB Comparison
TYRA vs KELYB Comparison
Compare TYRA & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- KELYB
- Stock Information
- Founded
- TYRA 2018
- KELYB 1946
- Country
- TYRA United States
- KELYB United States
- Employees
- TYRA N/A
- KELYB N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- KELYB Professional Services
- Sector
- TYRA Health Care
- KELYB Consumer Discretionary
- Exchange
- TYRA Nasdaq
- KELYB Nasdaq
- Market Cap
- TYRA 571.9M
- KELYB 483.4M
- IPO Year
- TYRA 2021
- KELYB N/A
- Fundamental
- Price
- TYRA $12.45
- KELYB N/A
- Analyst Decision
- TYRA Strong Buy
- KELYB
- Analyst Count
- TYRA 8
- KELYB 0
- Target Price
- TYRA $31.00
- KELYB N/A
- AVG Volume (30 Days)
- TYRA 235.9K
- KELYB 736.0
- Earning Date
- TYRA 11-06-2025
- KELYB 11-06-2025
- Dividend Yield
- TYRA N/A
- KELYB 2.20%
- EPS Growth
- TYRA N/A
- KELYB N/A
- EPS
- TYRA N/A
- KELYB N/A
- Revenue
- TYRA N/A
- KELYB $4,495,900,000.00
- Revenue This Year
- TYRA N/A
- KELYB $6.05
- Revenue Next Year
- TYRA N/A
- KELYB $4.18
- P/E Ratio
- TYRA N/A
- KELYB N/A
- Revenue Growth
- TYRA N/A
- KELYB 0.97
- 52 Week Low
- TYRA $6.42
- KELYB $11.04
- 52 Week High
- TYRA $29.60
- KELYB $21.22
- Technical
- Relative Strength Index (RSI)
- TYRA 58.97
- KELYB 50.12
- Support Level
- TYRA $11.70
- KELYB $14.00
- Resistance Level
- TYRA $12.55
- KELYB $15.05
- Average True Range (ATR)
- TYRA 0.68
- KELYB 0.00
- MACD
- TYRA -0.03
- KELYB -0.14
- Stochastic Oscillator
- TYRA 52.50
- KELYB 0.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About KELYB Kelly Services Inc. Class B
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services. The company's operations are divided into four business segments, namely Professional & Industrial, Science, Education, Outsourcing & Consulting Group, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions, including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.